P5844 - A Meta-Analysis About the Efficacy of Statins on Hepatic Venous Pressure Gradient (HVPG) in Cirrhosis Disease

Ibrahim Shanti, MD¹, Malik Samardali, MD², Abdul Muhsen Abdeen, MD², Tejas Joshi, MD³, Hafiz Ikram, MD², Wesam Frandah, MD³, Ahmed Sherif, MD³
1Marshall University - - Huntington, WV, Huntington, WV; 2Joan C. Edwards School of Medicine, Marshall University, Huntington, WV; 3Marshall University Joan C. Edwards School of Medicine, Huntington, WV

Introduction: Background. Portal hypertension is a common consequence in cirrhosis and can cause variceal bleeding, ascites and hepatic encephalopathy. It is defined as elevation of hepatic venous pressure gradient (HVPG) >5 mmHg. Statins may enhance HVPG in patients with liver cirrhosis (LC).

This meta-analysis aimed to assess the impact of statins use on HVPG among patients suffering from LC.

Methods: Methods. We systematically searched seven databases to extract relevant papers. Version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2) was used to assess the risk of bias for randomized controlled trials. The statistical analyses were carried out using Comprehensive Meta-Analysis version 3 (Biostat Inc., USA). Standard mean difference (SMD) with 95% confidence intervals (CIs) was calculated for hepatic venous pressure gradient using random effects.

Results: Results. The literature search found seven randomized controlled trials (RCT). Among the included studies, two were regarded as having a high risk of bias, while one study presented some concerns. However, four studies were rated as having a low risk of bias. Our results showed that statin treatment could significantly decrease the value HVPG comparing with control group (SMD: -0,613; 95% CI: -1,179 to -0,046; p = 0,034) as presented by the forest plot analysis. However, a high heterogeneity was detected among studies: Chi² = 34,28, p = 0,000, I² = 82%.

Discussion: Conclusions. This meta-analysis suggested that statins decreased HVPG and improved liver function in patients with cirrhosis. But, the beneficial effects of statins should be confirmed in long-term clinical trials for portal hypertension.


Figure: Figure 1-Our results showed that statin treatment could significantly decrease the value HVPG comparing with control group (SMD: -0,613; 95% CI: -1,179 to -0,046; p = 0,034) as presented by the forest plot analysis. However, a high heterogeneity was detected among studies: Chi2 = 34,28, p = 0,000, I2 = 82% .


Disclosures:
Ibrahim Shanti indicated no relevant financial relationships.
Malik Samardali indicated no relevant financial relationships.
Abdul Muhsen Abdeen indicated no relevant financial relationships.
Tejas Joshi: Salix, Gilead, Echosens – Advisor or Review Panel Member, Consultant, Grant/Research Support.
Hafiz Ikram indicated no relevant financial relationships.
Wesam Frandah: Boston Scientific – Advisor or Review Panel Member, Consultant. Merritt – Consultant. Olympus corporation of America – Consultant.
Ahmed Sherif indicated no relevant financial relationships.

Ibrahim Shanti, MD¹, Malik Samardali, MD², Abdul Muhsen Abdeen, MD², Tejas Joshi, MD³, Hafiz Ikram, MD², Wesam Frandah, MD³, Ahmed Sherif, MD³. P5844 - A Meta-Analysis About the Efficacy of Statins on Hepatic Venous Pressure Gradient (HVPG) in Cirrhosis Disease, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.